CD52 and hemophagocytic syndrome: Previous studies have demonstrated that anti-thymocyte globulin [18], tumor necrosis factor-alpha antagonists [19], anti-CD52 monoclonal antibody [9], anti-CD20 monoclonal antibody [20], and the DEP regimen [6] can be used as salvage therapy for refractory EBV-HLH.